Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease.
Publication/Presentation Date
4-1-2005
Abstract
Human T-lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an immune-mediated inflammatory disorder of the central nervous system. Immune activation in the host, which results from high levels of persistent antigenic stimulation and from transactivation of host immunoregulatory genes by HTLV-I, appears important in the pathogenesis of HAM/TSP. In a single-center, open-label trial, 12 patients with HAM/TSP were treated with doses of interferon-beta1a of up to 60mug twice weekly, based on its antiviral and immunomodulatory effects. Primary end points were immunological and virological measures that are potential biomarkers for HAM/TSP. Interferon-beta1a therapy reduced the HTLV-I tax messenger RNA load and the frequency of potentially pathogenic HTLV-I-specific CD8(+) cells. The HTLV-I proviral DNA load remained unchanged. Spontaneous lymphoproliferation, a marker of T-cell activation in HAM/TSP, also was reduced. Some measures of motor function were improved, and no significant clinical progression occurred during therapy. These results indicate that interferon-beta1a may beneficially affect the immune mechanisms central to the pathogenesis of HAM/TSP.
Volume
57
Issue
4
First Page
526
Last Page
534
ISSN
0364-5134
Published In/Presented At
Oh, U., Yamano, Y., Mora, C. A., Ohayon, J., Bagnato, F., Butman, J. A., Dambrosia, J., Leist, T. P., McFarland, H., & Jacobson, S. (2005). Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Annals of neurology, 57(4), 526–534. https://doi.org/10.1002/ana.20429
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
15786444
Department(s)
Administration and Leadership
Document Type
Article